measure and psoriatic arthritis Archives

Abstract Number: 1696 • ACR/ARHP Annual Meeting 2016
Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
Frank Behrens¹, Michaela Koehm², Eva Christina Schwaneck³, Marc Schmalzing⁴, Holger Gnann⁵, Gerd Greger⁶, Hans-Peter Tony⁷ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ³Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ⁴Rheumatology/Clinical Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ⁵Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁶AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, ⁷Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany
Background/Purpose: Minimal disease activity (MDA) is an important goal for patients with rheumatologic disorders, including psoriatic arthritis (PsA). The assessment of MDA could potentially help…
Abstract Number: 1700 • ACR/ARHP Annual Meeting 2016
Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: PASDAS is a composite disease activity measure (range 0–10) for psoriatic arthritis (PsA). Recently, PASDAS disease activity cutoffs were proposed and a minimal disease…
Abstract Number: 2780 • ACR/ARHP Annual Meeting 2016
A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Psoriatic Arthritis Disease Activity Score (PASDAS) is a newly developed composite disease activity measure that summarizes psoriatic arthritis (PsA) disease activity with a…
Abstract Number: 655 • ACR/ARHP Annual Meeting 2015
Rasch Analysis of the Hospital Anxiety and Depression Scale in Psoriatic Arthritis: Results from the Presta Study.
Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Heather Jones⁴, Amit Chhabra⁵ and Philip S. Helliwell⁶, ¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁵Pfizer Inc, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Hospital Anxiety and Depression Scale (HADs) is a generic measure of psychological status comprising anxiety and depression subscales. The aim of this study…

Abstracts tagged "measure and psoriatic arthritis"

Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab

Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa

A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life

Rasch Analysis of the Hospital Anxiety and Depression Scale in Psoriatic Arthritis: Results from the Presta Study.